Clinical trials document average reductions of 510% in LDL cholesterol and 1520% in triglycerides among GLP-1 users
Menopausal hormone therapy and tirzepatide for weight loss in postmenopausal women. The Lancet , 2025
10.1111/jgh.16619 50 WangR.LiA.PangZ
Compliance and rebound weight gain are real concerns that are not talked about enough
Cardiovascular outcomes trials show sustained benefits for heart health, blood pressure, and metabolic function
An FDA import alert to protect Americans At the end of May, a non-FDA unregistered company in China, Chengdu Miao Ding Xin Pharmaceutical Technology Co., Ltd., shipped nearly 10 kilograms of tirzepatide four million starting doses in three separate shipments intended for compounding (Shipment IDs: H77-0230371-7/13/1, H77-0230371-7/13/2, H77-0230371-7/13/3)